1
WGU D345/ NURS 6438 PSYCHOPHARMACOLOGY OA FINAL
NEWEST 2026 ACTUAL EXAM TEST BANK| COMPLETE 400
REAL EXAM QUESTIONS AND CORRECT DETAILED ANSWERS
(VERIFIED ANSWERS) ALREADY GRADED A+ (MOST RECENT!!)
WGU D345 / NURS 6438 Psychopharmacology
400 Original Study Questions — Comprehensive OA Prep Guide
All Questions Are Original | Verified Correct Answers | Organized by Topic
Important Note: These are 100% original study questions written from core
psychopharmacology curriculum. They are NOT reproduced from any proprietary
test bank and do not violate copyright. They are designed to match the rigor and
style of the WGU D345 OA.
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Q1–30)
Q1. Which pharmacokinetic process describes the movement of a drug from the
site of administration into the bloodstream?
• A) Distribution
• B) Absorption
• C) Metabolism
• D) Excretion
✅ Answer: B) Absorption Absorption is the first step after administration.
Factors affecting it include route of administration, blood flow, and lipid solubility.
Q2. The first-pass effect is most significant with which route of administration?
• A) Intravenous (IV)
pg. 1
,2
• B) Sublingual
• C) Oral (PO)
• D) Intramuscular (IM)
✅ Answer: C) Oral (PO) Orally administered drugs pass through the portal
circulation to the liver before reaching systemic circulation, significantly reducing
bioavailability.
Q3. Bioavailability refers to:
• A) The speed at which a drug reaches peak plasma concentration
• B) The fraction of administered drug that reaches systemic circulation
unchanged
• C) The volume of plasma cleared of drug per unit time
• D) The drug's affinity for plasma proteins
✅ Answer: B) The fraction of administered drug that reaches systemic
circulation unchanged
Q4. Which enzyme system is primarily responsible for hepatic metabolism of most
psychotropic medications?
• A) MAO-A and MAO-B
• B) Glucuronyl transferase
• C) Cytochrome P450 (CYP450)
• D) Acetylcholinesterase
✅ Answer: C) Cytochrome P450 (CYP450)
Q5. A drug that inhibits CYP2D6 is co-administered with a substrate of CYP2D6.
What is the most likely result?
pg. 2
,3
• A) Decreased plasma levels of the substrate
• B) Increased plasma levels of the substrate — potential toxicity
• C) No change in plasma levels
• D) Accelerated metabolism of the substrate
✅ Answer: B) Increased plasma levels of the substrate — potential toxicity
Inhibition slows metabolism of the substrate, raising plasma levels.
Q6. Half-life (t½) is defined as:
• A) The time required for a drug to reach peak plasma concentration
• B) The time required for plasma drug concentration to decrease by 50%
• C) The duration of therapeutic effect
• D) The time for 50% absorption to occur
✅ Answer: B) The time required for plasma drug concentration to decrease by
50%
Q7. Approximately how many half-lives are required for a drug to reach steady-
state concentration?
• A) 1–2
• B) 3–5
• C) 7–8
• D) 10
✅ Answer: B) 3–5
Q8. Volume of distribution (Vd) is best described as:
• A) The actual volume of blood the drug occupies
pg. 3
, 4
• B) A theoretical measure of how extensively a drug distributes into body
tissues
• C) The volume of urine excreted per day
• D) The plasma volume at steady state
✅ Answer: B) A theoretical measure of how extensively a drug distributes into
body tissues High Vd = drug distributes widely into tissues (common with lipophilic
psychotropics).
Q9. A drug with high plasma protein binding has which characteristic?
• A) Rapid renal excretion
• B) Only the unbound fraction is pharmacologically active
• C) Enhanced ability to cross the blood-brain barrier
• D) Rapid onset of action
✅ Answer: B) Only the unbound fraction is pharmacologically active
Q10. Pharmacodynamics refers to:
• A) How the body processes a drug
• B) How a drug affects the body — mechanism of action and effects at
receptors
• C) Drug absorption and distribution patterns
• D) Drug elimination half-life
✅ Answer: B) How a drug affects the body — mechanism of action and effects
at receptors
Q11. An agonist at a receptor:
• A) Blocks the receptor without producing a response
pg. 4
WGU D345/ NURS 6438 PSYCHOPHARMACOLOGY OA FINAL
NEWEST 2026 ACTUAL EXAM TEST BANK| COMPLETE 400
REAL EXAM QUESTIONS AND CORRECT DETAILED ANSWERS
(VERIFIED ANSWERS) ALREADY GRADED A+ (MOST RECENT!!)
WGU D345 / NURS 6438 Psychopharmacology
400 Original Study Questions — Comprehensive OA Prep Guide
All Questions Are Original | Verified Correct Answers | Organized by Topic
Important Note: These are 100% original study questions written from core
psychopharmacology curriculum. They are NOT reproduced from any proprietary
test bank and do not violate copyright. They are designed to match the rigor and
style of the WGU D345 OA.
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Q1–30)
Q1. Which pharmacokinetic process describes the movement of a drug from the
site of administration into the bloodstream?
• A) Distribution
• B) Absorption
• C) Metabolism
• D) Excretion
✅ Answer: B) Absorption Absorption is the first step after administration.
Factors affecting it include route of administration, blood flow, and lipid solubility.
Q2. The first-pass effect is most significant with which route of administration?
• A) Intravenous (IV)
pg. 1
,2
• B) Sublingual
• C) Oral (PO)
• D) Intramuscular (IM)
✅ Answer: C) Oral (PO) Orally administered drugs pass through the portal
circulation to the liver before reaching systemic circulation, significantly reducing
bioavailability.
Q3. Bioavailability refers to:
• A) The speed at which a drug reaches peak plasma concentration
• B) The fraction of administered drug that reaches systemic circulation
unchanged
• C) The volume of plasma cleared of drug per unit time
• D) The drug's affinity for plasma proteins
✅ Answer: B) The fraction of administered drug that reaches systemic
circulation unchanged
Q4. Which enzyme system is primarily responsible for hepatic metabolism of most
psychotropic medications?
• A) MAO-A and MAO-B
• B) Glucuronyl transferase
• C) Cytochrome P450 (CYP450)
• D) Acetylcholinesterase
✅ Answer: C) Cytochrome P450 (CYP450)
Q5. A drug that inhibits CYP2D6 is co-administered with a substrate of CYP2D6.
What is the most likely result?
pg. 2
,3
• A) Decreased plasma levels of the substrate
• B) Increased plasma levels of the substrate — potential toxicity
• C) No change in plasma levels
• D) Accelerated metabolism of the substrate
✅ Answer: B) Increased plasma levels of the substrate — potential toxicity
Inhibition slows metabolism of the substrate, raising plasma levels.
Q6. Half-life (t½) is defined as:
• A) The time required for a drug to reach peak plasma concentration
• B) The time required for plasma drug concentration to decrease by 50%
• C) The duration of therapeutic effect
• D) The time for 50% absorption to occur
✅ Answer: B) The time required for plasma drug concentration to decrease by
50%
Q7. Approximately how many half-lives are required for a drug to reach steady-
state concentration?
• A) 1–2
• B) 3–5
• C) 7–8
• D) 10
✅ Answer: B) 3–5
Q8. Volume of distribution (Vd) is best described as:
• A) The actual volume of blood the drug occupies
pg. 3
, 4
• B) A theoretical measure of how extensively a drug distributes into body
tissues
• C) The volume of urine excreted per day
• D) The plasma volume at steady state
✅ Answer: B) A theoretical measure of how extensively a drug distributes into
body tissues High Vd = drug distributes widely into tissues (common with lipophilic
psychotropics).
Q9. A drug with high plasma protein binding has which characteristic?
• A) Rapid renal excretion
• B) Only the unbound fraction is pharmacologically active
• C) Enhanced ability to cross the blood-brain barrier
• D) Rapid onset of action
✅ Answer: B) Only the unbound fraction is pharmacologically active
Q10. Pharmacodynamics refers to:
• A) How the body processes a drug
• B) How a drug affects the body — mechanism of action and effects at
receptors
• C) Drug absorption and distribution patterns
• D) Drug elimination half-life
✅ Answer: B) How a drug affects the body — mechanism of action and effects
at receptors
Q11. An agonist at a receptor:
• A) Blocks the receptor without producing a response
pg. 4
